Table 1 Characterization of anti-CD3 Fabs binding to different CD3E/D variants by SPR.

From: Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

Fab

Human CD3E/D

Cyno CD3E/D

Murine CD3E/D

Chimeric human/ murine CD3E/D

KD (nM)

KD (nM)

KD (nM)

KD (nM)

hCD3.1

6.3 ± 0.18

6.5 ± 0.11

NB

8.6 ± 0.53

hCD3.2

3.1 ± 0.35

3.8 ± 0.61

NB

4.2 ± 0.22

hCD3.3

0.77 ± 0.13

0.91 ± 0.17

NB

0.81 ± 0.06

hCD3.4

2.7 ± 0.45

2.7 ± 0.02

NB

3.1 ± 0.23

hCD3.5

4.1 ± 0.44

5.0 ± 0.5

NB

4.4 ± 0.27

SP34

6.6 ± 0.46

7.5 ± 0.06

NB

7.3 ± 0.18

2C11

NB

NB

22.0 ± 1.4

250 ± 16

  1. NB no binding.